Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in
the world. Metabolic reprogramming is considered a new hallmark of cancer, but it remains …

Despite advances in the treatment of cancers through surgical procedures and new
pharmaceuticals, the treatment of hepatocellular carcinoma (HCC) remains challenging as …

Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …

Understanding genetic aberrations in cancer leads to discovery of new targets for cancer
therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully …

In the past decade, there has been a resurgence of interest in elucidating how metabolism is
altered in cancer cells and how such dependencies can be targeted for therapeutic gain. At …

Oncogenic signaling involved in tumor metabolic reprogramming. Tumorigenesis was not
only determined by the mutations or deletion of oncogenes but also accompanied by the …

Cancer progression results from activation of various signaling networks. Among these,
PI3K/Akt signaling contributes to proliferation, invasion, and inhibition of apoptosis …

Hepatocellular carcinoma (HCC) poses a significant global health concern, with its
incidence steadily increasing. The development of HCC is a multifaceted, multi-step process …

Hepatocellular carcinoma (HCC) is an aggressive tumor, with a high mortality rate due to
late symptom presentation and frequent tumor recurrences and metastasis. It is also a …

Metabolic reprogramming plays a crucial role in the development of hepatocellular
carcinoma (HCC). However, the key drivers of metabolic reprogramming underlying HCC …